Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00170001 · ClinicalTrials.gov registry record · NA
Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 500
- Enrollment target
NCT00170001: Completed NA study, sponsored by Mayo Clinic.
NCT00170001 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00170001, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
Study Summary
The investigators hypothesize that persons with the particular cluster of symptoms that are due to supraesophageal reflux (SER) will have complete resolution of those symptoms with adequate acid suppression when a PPI is administered for 6 months.
Interventions
- DRUG Sugar Pill
- DRUG Nexium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00170001
The ClinicalTrials.gov registry entry for NCT00170001 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sugar Pill is the first listed.
NCT00170001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00170001 about?
NCT00170001 is a clinical study titled "Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy". The investigators hypothesize that persons with the particular cluster of symptoms that are due to supraesophageal reflux (SER) will have complete resolution of those symptoms with adequate acid suppression when a PPI is administered for 6 months.
What is the current status of trial NCT00170001?
This trial is currently completed. It is a NA study. The enrollment target is 500 participants. The study started on 2005-04. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00170001?
The interventions under investigation include: Sugar Pill (DRUG), Nexium (DRUG).
Who is sponsoring clinical trial NCT00170001?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.